Given the well-established synthetic lethality between BRCA deficiency and PARP inhibition, our objective was to evaluate PARPi sensitivity in hATM-deficient cancer cell lines relative to hBRCA2-deficient cells. The gene discussed is PARP1; the disease is cancer.